Complement C3 is a novel modulator of the anti-factor VIII immune response

Development of neutralizing antibodies against therapeutic Factor VIII (FVIII) is the most serious complication of the treatment of hemophilia A. There is growing evidence to show the multifactorial origin of the anti-FVIII immune response, combining both genetic and environmental factors. While a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Rayes, Julie, Ing, Mathieu, Delignat, Sandrine, Peyron, Ivan, Gilardin, Laurent, Vogel, Carl-Wilhelm, Fritzinger, David C., Frémeaux-Bacchi, Véronique, Kaveri, Srinivas V., Roumenina, Lubka T., Lacroix-Desmazes, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792280/
https://www.ncbi.nlm.nih.gov/pubmed/29146705
http://dx.doi.org/10.3324/haematol.2017.165720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792280/
https://www.ncbi.nlm.nih.gov/pubmed/29146705
http://dx.doi.org/10.3324/haematol.2017.165720

Ejemplares similares